Updated:
COMPASS Pathways
COMPASS Pathways was founded in 2016 in London by physician Ekaterina Malievskaia and her husband, entrepreneur George Goldsmith, after a personal family...
COMPASS Pathways
COMPASS Pathways was founded in 2016 in London by physician Ekaterina Malievskaia and her husband, entrepreneur George Goldsmith, after a personal family experience with treatment-resistant depression. The firm designs, develops, and commercializes psychedelic therapies, with its lead asset being COMP360, a proprietary synthetic psilocybin formulation administered in controlled therapeutic settings. It operates as a publicly traded biopharmaceutical company on Nasdaq, not as a family office — though it began with early-stage venture backing from investors including Peter Thiel and Mike Novogratz. The firm's strategy centers on a single-molecule, single-indication regulatory play. Capital is deployed into Phase II and Phase III clinical trials investigating COMP360 for treatment-resistant depression, anorexia nervosa, and post-traumatic stress disorder. The company has established a network of clinical research sites across the United States, United Kingdom, and Europe. Notable early backers include atai Life Sciences, which co-led Series A funding, and institutional investors who participated in the 2020 IPO that raised $146M at $17 per share (per Nasdaq, 2020). Unlike broad psychedelic platforms, COMPASS retains a narrow pipeline, a defined synthetic drug product, and an integrated psychological support protocol that would be co-administered by certified therapists. The firm reported 191 full-time employees as of its Q1 2023 earnings filing and maintains its R&D headquarters in London with a commercial team in New York. In the first quarter of 2024, the company announced the launch of a Phase III clinical study for COMP360 in anorexia nervosa (per the firm, 2024). Adjacent structures include a therapist training program and a digital patient-facing tool designed to support therapy sessions, though neither operates as a separate philanthropic or investment vehicle. The board includes senior figures from the U.S. Department of Veterans Affairs and global regulatory bodies. COMPASS differs structurally from most biotechs toggling between venture funding and public markets: its entire valuation thesis rests on DEA Schedule I policy reform enabling reimbursable clinical delivery of a psychedelic compound. The company must navigate both FDA drug approval and Drug Enforcement Administration rescheduling in parallel, a dual-regulatory burden that shapes its capital allocation and partnership logic far more than a typical central nervous system drug developer. Success would also require building an entirely new therapist-certification infrastructure for a novel class of therapy.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
George Goldsmith
Co-Founder
Ekaterina Malievskaia
Co-Founder
Sector focus
Frequently asked questions
Who runs clinical strategy and drug development at COMPASS Pathways?
Dr. Ekaterina Malievskaia co-founded the company and served as Chief Innovation Officer, directly overseeing its clinical pipeline and regulatory strategy. Dr. Guy Goodwin was appointed Chief Medical Officer in 2018, bringing decades of psychiatry research to the Phase II and III programs. The company's management structure blends scientific leadership from both co-founders with an experienced clinical trials organization.
How is COMPASS Pathways funded, and who are its early institutional backers?
COMPASS raised venture capital from backers including Peter Thiel, Mike Novogratz, and atai Life Sciences before its 2020 IPO on Nasdaq. The IPO raised $146 million at a valuation north of $1 billion. Since going public, the firm has been funded through secondary equity raises and at-the-market offerings, making it directly dependent on public-market confidence in psychedelic medicine.
What is the regulatory pathway for psilocybin-based therapy, and how does COMPASS navigate it?
COMPASS's COMP360 psilocybin formulation must clear both FDA clinical-trial hurdles and Drug Enforcement Administration rescheduling. The FDA granted breakthrough therapy designation in 2018 for treatment-resistant depression, which accelerates development and review. The company must also show that a Schedule I substance can be safely administered in a therapist-supervised setting, a novel regulatory challenge that adds complexity to every Phase III trial.
Does COMPASS Pathways hold any intellectual property advantage beyond the molecule itself?
Yes. COMPASS holds a portfolio of patents covering not just the synthetic psilocybin crystalline form but also the associated psychological support model, therapist training protocols, and the physical environment in which treatment is administered. This 'therapy plus setting' IP strategy is designed to create a broader protective moat than a standard drug patent.
How does COMPASS Pathways relate to other psychedelic investment vehicles or family offices in the space?
COMPASS is a public biotech, not a family office or investment platform. Its relationship to early family-office capital, such as that of Peter Thiel, was as a portfolio company, and that capital was significantly diluted at IPO. Today the firm trades on Nasdaq, and its shareholder register likely includes dedicated biotech funds and thematic ETFs rather than direct family-office allocations.
What investment stages or asset classes does COMPASS participate in?
COMPASS does not invest in other companies, funds, or asset classes. It is a single-operating entity that deploys raised capital solely into clinical trials, manufacturing scale-up for its own synthetic psilocybin, and therapist-training infrastructure. There is no external venture or fund-commitment program.
What are the most significant risk factors an allocator should weigh when evaluating COMPASS as a public equity holding?
The enterprise value is almost entirely tied to Phase III outcomes for a Schedule I substance. Binary clinical trial risk is compounded by political volatility around DEA rescheduling. The firm also faces smaller, nimbler competitors pursuing FDA pathways and a potential gray market of natural psilocybin, which could undermine a synthetic-patent strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: